Regeneron is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power
Are C-level execs really listening to the brouhaha over drug prices? With new drugs still rolling out in the U.S. at big premiums, one might think not. But if Regeneron chief Leonard Schleifer is speaking for his colleagues, then the answer is yes.
Long dominated by global behemoths like Johnson & Johnson and Pfizer, this executive-pay ranking now includes almost as many biotechs as pharma companies.
Last year, little Regeneron gave its top executives a big payday. The company's vision-loss drug Eylea was breaking sales records left and right. Its colon cancer drug, developed with Sanofi, had hit the market. And the company's board figured that keeping its key people was worth millions--a total of $140 million, in fact, mostly in stock and option awards.
After 25 years at the helm of one of biotech's best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company's blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive's most profitable work may still be ahead of him.
With a new blockbuster drug and more potential hits in development, Regeneron Pharmaceuticals has been successful long enough for top executives to consider the challenges of keeping the entrepreneurial culture behind the R&D streak alive. Read more >>
Who in this business hasn't seen billions incinerated in pursuit of sheer folly? Influential today is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs. And intelligent research strategies are far more rare than we acknowledge. You'll find some here in our second annual report on the 25 most influential people in the industry (find last year's report here). Check out the list >>